Journal
ARTHRITIS RESEARCH & THERAPY
Volume 12, Issue 2, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/ar2977
Keywords
-
Categories
Ask authors/readers for more resources
Recent preclinical and clinical studies lend support to the notion that B-cell depletion is a promising therapeutic target in patients with diffuse cutaneous systemic sclerosis. A recent open-label trial provides further evidence showing marked effects of rituximab treatment on skin thickening, functional ability, and disease activity in conjunction with effects on lesional and circulating B cells and on interleukin-6 and BAFF (B-cell activating factor of tumor necrosis factor family). The excellent safety profile of rituximab in this and other trials warrants further well-designed clinical trials in larger patient groups combined with comprehensive biomarker studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available